14 results about "Peptide display" patented technology

Provided is a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 59, or a pharmaceutically acceptable salt thereof.

This invention provides a method for screening peptides that specifically target T cells, comprising providing T cells having a subset selected from CD1, CD2, CD3, CD4, CD5, CD7, CD8, CD16, CD25, CD26, CD27, CD28, CD30, CD38, CD39, CD40L, CD44, CD45, CD62L, CD69, CD73, CD80, CD83, CD86, CD95, CD103, CD119, CD126, CD150, CD152 (CTLA-4), CD153, CD154 (CD40L) The T cells are labeled with at least one of the following surface antigen markers: CD161, CD183, CD223, CD254, CD275, CD45RA, CXCR3, CXCR5, FasL, IL18R1, CTLA-4, OX40, GITR, LAG3, ICOS, PD-1, leu-12, TCR, TLR1, TLR2, TLR3, TLR4, TLR6, NKG2D, CCR, CCR1, CCR2, CCR4, CCR6, and CCR7. The T cells are then contacted with a peptide display library, and target peptides that specifically bind to the T cells are screened therefrom.

The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and / or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and / or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and / or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and / or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

The present invention relates to a method for identifying candidate peptides presented by major histocompatibility complex (MHC), for vaccination, inducing immune tolerance, blocking TCR, MHC-mediated toxin delivery and redirecting T cells with CAR, for immunogenicity testing and other in vitro T cell reactivity testing. The present invention further relates to a method for determining the MHC binding affinity of a candidate peptide.

To provide methods for screening peptides that specifically bind to a target site of a living organism and such peptides.SOLUTION: Disclosed herein is a method for screening peptides that specifically bind to a target site of a living organism, comprising the steps of: (a) administering to a non-human living organism a phage population displaying a peptide library; (b) separately recovering a population of phages that bound to the target site and a population of phages that did not bind to the target site; (c) reading the base sequences encoding peptides displayed by the target site binding phage population and the base sequences encoding peptides displayed by the phage population not bound to the target site using a next generation sequencer, to obtain a lead population of base sequences encoding peptides presented by the target site-binding phage population (target site lead population) and a non-target site lead population, where the peptides encoded by leads in the target site lead population but not contained in the non target site lead population are the peptides that specifically bind to the target site of the living organism.SELECTED DRAWING: None

The present disclosure provides antigen binding proteins that specifically bind to the Newton esophageal squamous cell carcinoma 1 (NY-ESO-1) peptide displayed by the HLA, as well as therapeutic and diagnostic methods of using these binding proteins. The antigen binding proteins of the present disclosure bind to HLA-displayed NY-ESO-1 with a high degree of specificity, but do not bind to HLA-displayed peptides that differ from 2, 3, 4, 5 or more amino acids.

The application provides a mycobacterium tuberculosis small peptide display library and a construction method and application thereof, and the construction method comprises the following steps: S1, small peptide sequence information is obtained by intercepting according to mycobacterium tuberculosis proteome sequence information; S2, the amino acid sequence of the small peptide sequence information is converted into a codon sequence, sequence optimization is carried out, and after a consensus sequence is added, oligonucleotide sequence information is obtained; S3, an oligonucleotide physical object is synthesized in a large scale and in parallel by using a chemical method; S4, PCR amplification is carried out by taking the oligonucleotide physical object as a template, and after being digested by a restriction endonuclease, an inserted nucleic acid fragment is obtained; and S5, the inserted nucleic acid fragment is used to construct the small peptide display library by using a display system. The mycobacterium tuberculosis small peptide display library constructed by the application provides important tools and resources for systematically understanding mycobacterium tuberculosis immunological epitopes, vaccine development, new drug research and development and the like.

The present invention relates to a peptide binding to mesothelin, and use thereof, wherein the peptide of the present invention specifically binds to mesothelin and inhibits same, and thus the effect of inhibiting the migration and metastasis of cancer cells is exhibited, wherein it has been identified that the peptide of the present invention was selected, using a phage peptide display technology, as one type of peptide that easily binds to cells in which human mesothelin is highly expressed, and thus the peptide binds to mesothelin and inhibits the migration of cancer cells, and the peptide of the present invention is relatively stable in serum, and thus exhibits high potential as an anti-cancer therapeutic agent for inhibiting metastasis according to cancer progression and migration in the future, an anti-cancer drug delivery probe, and a cancer diagnostic probe.

The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and / or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

Provided is a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 59, or a pharmaceutically acceptable salt thereof.

To provide a novel cyclization method for peptide compounds to construct a peptide display library, and to provide methods for the synthesis of branched peptides.SOLUTION: Provided is a method for producing a peptide compound having a cyclic portion, the method comprising: 1) translating and synthesizing an acyclic peptide compound from a nucleic acid encoding the peptide compound composed of an amino acid residue and / or amino acid analog residue, or an amino acid residue and / or amino acid analog residue and N-terminal carboxylic acid analog, the acyclic peptide compound containing an amino acid residue or amino acid analog residue having a reactive site in one of its side chains, and an amino acid, amino acid analog residue or N-terminal carboxylic acid analog with another reactive site at the N-terminus; and 2) forming a carbon-carbon bond between the reactive site of the N-terminal amino acid residue, N-terminal amino acid analog residue, or N-terminal carboxylic acid analog and the reactive site of the amino acid residue or amino acid analog having a reactive site in one of its side chains.SELECTED DRAWING: None